The FDA has declared an end to the Ozempic and Wegovy shortages from Novo Nordisk, confirming the pharmaceutical company's capacity to meet growing demand. This move limits the ability of compounding pharmacies to create unapproved cheaper alternatives, thereby strengthening Novo's market control. Analysts project potential market growth for these semaglutide therapies could reach between $100 billion and $150 billion annually by the early 2030s. Novo Nordisk's strategic investments in expansion and workforce enhancement position the firm well to capitalize on this stability.
"The FDA has confirmed that the Ozempic and Wegovy shortage is over, enabling Novo Nordisk to meet the rising demand for its semaglutide therapies."
"This resolution could reinforce Novo Nordisk's dominance in the semaglutide market, which is projected to reach $100 billion to $150 billion annually by the early 2030s."
Collection
[
|
...
]